(813) 684-6000

Research

Bay Area Cardiology physicians have been participating in clinical research since 1992. Since then we have been involved in over 90 studies both nationally and internationally. Through patient-oriented research Bay Area Cardiology seeks to improve treatments and outcomes.

Bay Area Cardiology is proud of its dedicated team of four full time professionals who are experienced at coordinating trials and maintaining a high standard of quality and performance.

Our experience with clinical trials includes registries, investigational medications, FDA post market approved drugs, coronary stents, peripheral stents, carotid stents, pacemakers, Bi-V and AICD devices. Our participation is limited to only Phase III or Phase IV studies.

We participate in both office and hospital based studies that cover a wide variety of cardiac and vascular medicine and treatments.

Our current enrolling studies include new diagnosis of Atrial Fibrillation, Pulmonary Arterial Hypertension and Congestive Heart Failure.

The following are a few examples of clinical studies we have participated in:

ADAPTA (Medtronic) A randomized trial to compare single-chamber atrial (AAl) and Dual-chamber (DDD) pacing in patients with Sick Sinus Syndrome

– Ranked #1 out of 100 sites

– PI: Dr. Mester

RELY (Boehringer Ingelheim) Randomized Evaluation of Outcomes of Long Term Anticoagulant therapy.

– Ranked #9 out of 952 sites
– PI: Dr. Khant

HCRI DAPT (Harvard Clinical Research Institute) A prospective, multi- centered, randomized, double-blind trial to assess the effectiveness and safety of 12 month versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention(PCI) with either drug- eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.

– Ranked #28 out of 174 sites

– PI: Dr.Tamboli

XIENCE V USA (Abbott Vascular) Xience V Everolimus Eluting Coronary Stent System (EECSS) USA post-Approval Study.

– Ranked #3 out of 210 sites

– PI: Dr. Tamboli

RATE (St. Jude Medical) Registry of AT/AF Episodes in the CRM Device Population

– Ranked #5 out of 19 sites

– PI: Dr. Betzu

PREDETERMINE (NIHL) Markers of Sudden Cardiac Death Registry

– Ranked #6 out of 105 sites

– PI: Dr. Bugni

TRANSLATE (DCRI) TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome

– Ranked #55 out of 233

– PI: Dr. Rodriguez

PROMUS (Boston Scientific) PROMUS Element Plus US Post-Approval Study

– Ranked #6 out of 52 sites

– PI: Dr. Tamboli

IMPROVE IT (Merck/Schering Plough) IMProved Reduction of Outcomes: Vytorin Efficacy International Trial

– Ranked #67 out of 359 sites

– PI: Dr. Betzu

CAMELLIA (Eisai) A Randomized, Double-blind, Placebo-controlled, Parallel- group Study to Evaluate the Long-term Treatment with BELVIQ (lorcaserin HCL) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.

– Ranked #3 out of 400 sites

– PI: Dr. Chokshi

REVEAL (Merck/Oxford University) HPS 3/ TIMI 55: REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease.

– Ranked #61 out of 151 sites

– PI: Dr. Khan

PAH (Actelion) Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program

– Ranked #22 out of 71 site

– PI: Dr. Dewhurst

ST SEGMENT (Medtronic) Virtuoso Implantable Cardioverter Defibrillator ST Segment Algorithm

– Ranked #4 out of 24 sites

– PI: Dr.Mester

1160.128 (Boehringer Ingelheim) A prospective, open label study evaluating the efficacy of two management strategies (pantoprazole 40 mg q a.m. and taking Pradaxa with food (within 30 minutes after a meal)) on gastrointestinal symptoms (GIS) in patients newly on treatment with Pradaxa 150 mg b.i.d. or 75 mg b.i.d. for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).

– Ranked #4 out of 26 sites

– PI: Dr. Khant

EFFECT-AF (Laser) An Atrial Fibrillation treatment registry

– Ranked #12 out of 54

– PI: Dr. Perzanowski